Newsroom | 5178 results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, an...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insul...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Hepta, a liquid biopsy company developing blood tests for chronic disease, today announced clinical data showing its blood test more accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) patients eligible for treatment than the three non-invasive tests recommended by current clinical guidelines: FIB-4, ELF, and FibroScan. The 528-patient, multi-cohort study will be presented at the European Association for the Study of the Liver (EAS...

PALO ALTO, Calif.--(BUSINESS WIRE)--Signos Inc., the company behind the first FDA-cleared, over-the-counter glucose monitoring system for weight management, today announced a $20 million funding round with investment from GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. As part of the partnership with Dexcom, Signos will be available for purchase on Stelo.com, Dexcom's direct-to-consumer CGM website, making it easier for people to find and access the Signos system. Signos ha...

SAN FRANCISCO--(BUSINESS WIRE)--Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting...

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool+ Direct Connect launches in Epic Showroom, bringing diabetes device data into clinician workflows with one click....

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study of the Liver Congress (EASL 2026) demonstrate that ARO-INHBE treatment led to clinically meaningf...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omn...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company’s quality control process. Sensors identified...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BreezeBio Announces Scientific Advisory Board to Support Next Stage of Precision Genetic Medicine Pipeline Development...